Abstract
Background: The current coronavirus disease 2019 (COVID-19) pandemic, since first reported in Wuhan, has inspired worldwide efforts to develop effective COVID-19 vaccination strategies. mRNA vaccines encoding COVID-19 antigens have emerged prominantlyin this global race due to their high effectiveness and simple manufacturing process. Notably, two COVID-19 mRNA vaccines, mRNA-1273 and BNT162b2, have survived in clinical trials and been authorized for emergency use across variouscountries.
Summary: Recent advances on mRNA vaccine development for COVID-19 are discussed in this perspective, including sequence design, chemical modification, manufacturing process, and in vivo delivery. Phase I to IV clinical trials of mRNA-1273 and BNT162b2 are then summarized, respectively.
Conclusion: Using mRNA vaccines is a promising strategy to achieve mass vaccination in the COVID-19 pandemic. We hope that future studies of mRNA vaccine technology will overcome existing limitations and help people cope with COVID-19.
Keywords: Coronavirus disease 2019 (COVID-19), SARS-CoV-2, mRNA vaccine, chemical modifications, mRNA- 1273, BNT162b2.
Current Medicinal Chemistry
Title:Perspectives and Prospects on mRNA Vaccine Development for COVID-19
Volume: 29 Issue: 23
Author(s): Lihui Jin, Zhenyuan Han, Pengjun Zhao*Kun Sun*
Affiliation:
- Pediatric Heart Center, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China
- Pediatric Heart Center, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China
Keywords: Coronavirus disease 2019 (COVID-19), SARS-CoV-2, mRNA vaccine, chemical modifications, mRNA- 1273, BNT162b2.
Abstract:
Background: The current coronavirus disease 2019 (COVID-19) pandemic, since first reported in Wuhan, has inspired worldwide efforts to develop effective COVID-19 vaccination strategies. mRNA vaccines encoding COVID-19 antigens have emerged prominantlyin this global race due to their high effectiveness and simple manufacturing process. Notably, two COVID-19 mRNA vaccines, mRNA-1273 and BNT162b2, have survived in clinical trials and been authorized for emergency use across variouscountries.
Summary: Recent advances on mRNA vaccine development for COVID-19 are discussed in this perspective, including sequence design, chemical modification, manufacturing process, and in vivo delivery. Phase I to IV clinical trials of mRNA-1273 and BNT162b2 are then summarized, respectively.
Conclusion: Using mRNA vaccines is a promising strategy to achieve mass vaccination in the COVID-19 pandemic. We hope that future studies of mRNA vaccine technology will overcome existing limitations and help people cope with COVID-19.
Export Options
About this article
Cite this article as:
Jin Lihui, Han Zhenyuan, Zhao Pengjun*, Sun Kun*, Perspectives and Prospects on mRNA Vaccine Development for COVID-19, Current Medicinal Chemistry 2022; 29 (23) . https://dx.doi.org/10.2174/0929867329666220216110931
DOI https://dx.doi.org/10.2174/0929867329666220216110931 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety and Efficacy of Immune Checkpoint Inhibitors in Children and
Young Adults with Haematological Malignancies: Review and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Racial/Ethnic Differences in Symptoms of Posttraumatic Stress Disorder
Current Psychiatry Reviews Potential Role of Polyphenols in the Prevention of Cardiovascular Diseases: Molecular Bases
Current Medicinal Chemistry Chemical and Genetic Engineering Strategies to Improve the Potency of Pharmaceutical Proteins and Enzymes
Current Medicinal Chemistry Pathophysiological Mechanisms of Stress-Induced Intestina Damage
Current Molecular Medicine Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry The Need for an Interdisciplinary Network of Investigations on HHT
Current Pharmaceutical Design The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews The Mammalian Innate Immune System: Potential Targets for Drug Development
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Design, Synthesis and ex vivo Study of the Vasorelaxant Activity Induced by Isosteric Derivatives of Dihydropyridines (NH→O)
Letters in Drug Design & Discovery Are we Genomic Mosaics? Variations of the Genome of Somatic Cells can Contribute to Diversify our Phenotypes
Current Genomics Patent Selections
Recent Patents on DNA & Gene Sequences Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer’s Disease: The Relationship with Other Atherosclerosis Risk Factors
Current Vascular Pharmacology Growth Velocity, Final Height and Bone Mineral Metabolism of Short Children Treated Long Term with Growth Hormone
Current Pharmaceutical Biotechnology PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Are Bacteriocins Underexploited? NOVEL Applications for OLD Antimicrobials
Current Pharmaceutical Biotechnology Spatial Segregation of Phosphatidylinositol 4,5-Bisphosphate (PIP2) Signaling in Immune Cell Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)